Survodutide vs Retatrutide: Dual vs Triple Agonist?
Survodutide activates two hormone receptors (GLP-1 and glucagon). Retatrutide activates three (GLP-1, GIP, and glucagon). Both are investigational drugs still in clinical trials. Neither is FDA approved as of mid-2026, but early data on each is striking enough that they are worth understanding before they potentially reach the market.
Quick Answer: Who Is Each One For?
Survodutide is being studied primarily for obesity and a liver condition called NASH (non-alcoholic steatohepatitis), which is liver damage caused by fat buildup. It targets both the appetite system (GLP-1) and the fat-burning system (glucagon) .
Retatrutide is being studied for obesity with one extra receptor activation (GIP), which appears to push weight loss even further than dual agonists in early trials .
Verdict: Both are promising next-generation weight loss drugs. Retatrutide's early Phase 2 data shows higher weight loss numbers, but neither is available outside clinical trials. Retatrutide hits more targets; survodutide has a particular focus on liver disease alongside obesity.
What Is Survodutide?
Survodutide is a drug that activates two hormone receptors at once: GLP-1 and glucagon. This type of drug is called a dual agonist, meaning it hits two targets instead of one.
GLP-1 receptor activation reduces appetite and slows digestion, the same pathway used by semaglutide (Ozempic). Glucagon receptor activation tells the liver to burn more fat and increases how many calories the body uses at rest.
Combining both pathways is designed to produce more fat loss than either target alone .
Survodutide is also being studied specifically for NASH (liver disease caused by fat), where reducing liver fat matters as much as total body weight .
What Is Retatrutide?
Retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist made by Eli Lilly.
It adds GIP receptor activation on top of the GLP-1 and glucagon combination. GIP is a gut hormone that works alongside GLP-1 to regulate insulin and may enhance fat metabolism .
Tirzepatide (Mounjaro, Zepbound) uses GLP-1 plus GIP. Retatrutide adds glucagon to that combination, making it a three-target drug.
Phase 2 trial data showed an average weight loss of approximately 24% of body weight at the highest dose after 48 weeks . If those numbers hold in Phase 3, retatrutide would outperform every weight loss drug currently on the market.
How Do Survodutide and Retatrutide Differ?
Do they work through the same pathways?
Partially. Both activate GLP-1 and glucagon receptors. Retatrutide also activates the GIP receptor, which survodutide does not.
What is each one primarily being studied for?
Survodutide: obesity and NASH (liver disease caused by excess fat). The liver disease angle is a distinguishing focus of its trial program .
Retatrutide: obesity, including in people without diabetes. Its trials have also explored type 2 diabetes applications .
What doses are being studied?
Survodutide: doses studied in Phase 2 trials range from 0.3 mg to 6 mg per week . Final approved doses, if it reaches approval, are not yet determined.
Retatrutide: Phase 2 trials tested doses from 1 mg to 12 mg per week . The highest dose group showed the most weight loss.
How much weight loss do early trials show?
Survodutide: Phase 2 data in people with obesity showed meaningful weight reduction compared to placebo, with higher doses producing more loss . Exact percentages require verification against the published trial data .
Retatrutide: Phase 2 data showed approximately 17% weight loss at 8 mg/week and approximately 24% at 12 mg/week over 48 weeks . These are not yet confirmed in Phase 3.
How strong is the evidence?
Both are at Phase 2 to Phase 3 stage as of mid-2026. Phase 2 results are promising but not definitive. Phase 3 trials, which are larger and more rigorous, will determine whether either drug reaches FDA approval .
Side-by-Side Comparison
| Survodutide | Retatrutide | |
|---|---|---|
| Mechanism | GLP-1 + glucagon dual agonist | GLP-1 + GIP + glucagon triple agonist |
| Manufacturer | Boehringer Ingelheim | Eli Lilly |
| Primary study focus | Obesity and NASH (liver disease) | Obesity and type 2 diabetes |
| Receptors activated | 2 (GLP-1, glucagon) | 3 (GLP-1, GIP, glucagon) |
| Trial stage (mid-2026) | Phase 2 to 3 | Phase 3 |
| Best Phase 2 weight loss | Significant vs placebo | ~24% at 12 mg/week over 48 wks |
| FDA approval | No | No |
| Injection frequency | Once weekly | Once weekly |
What Role Does Glucagon Play in Both Drugs?
Glucagon is a hormone most people associate with raising blood sugar. But at the right activation level, glucagon receptor stimulation also tells the liver to burn fat and increases the body's resting energy use .
Both survodutide and retatrutide use glucagon activation to add a fat-burning boost on top of the appetite-reducing effects of GLP-1. This is what separates them from semaglutide (GLP-1 only) and tirzepatide (GLP-1 plus GIP).
The trade-off is that glucagon activation can cause nausea and GI side effects at higher doses , which is one of the challenges in dose selection for both drugs.
Which Do People Pick, and When?
This is general guidance, not personalized medical advice. And a very important caveat: neither drug is available outside clinical trials right now.
People who end up on survodutide are typically enrolled in a clinical trial, often with obesity plus liver disease as a co-condition. The NASH angle makes it a potentially important drug for a population where there are few options.
People who end up on retatrutide are also typically in a clinical trial, usually focused on obesity. The Phase 2 weight loss data has generated significant interest from clinicians and researchers watching the obesity drug space.
Following the development of next-generation weight loss drugs takes some organization. If you are already on a protocol with existing approved compounds and want to stay informed, DoseVault helps you track what you are currently taking and make sense of your response data as newer options emerge.
Frequently Asked Questions
What is the difference between survodutide and retatrutide?
Survodutide is a dual GLP-1 and glucagon receptor agonist. Retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist. Both are investigational drugs not yet FDA approved. Retatrutide hits one additional receptor (GIP) compared to survodutide, which may contribute to greater weight loss in early trials .
Is survodutide FDA approved?
No. Survodutide is in Phase 2 and Phase 3 clinical trials as of mid-2026, primarily for obesity and NASH . It has not received FDA approval.
Is retatrutide FDA approved?
No. Retatrutide is in Phase 3 clinical trials for obesity as of mid-2026 . Phase 2 data showed approximately 24% weight loss at the highest dose over 48 weeks , which would be the largest seen in any weight loss drug trial if confirmed in Phase 3.
What does the glucagon receptor do in weight loss drugs?
Glucagon receptor activation tells the liver to burn more fat and increases resting energy use. Adding it to GLP-1 agonism may increase fat burning beyond what appetite reduction alone produces. This is why both survodutide and retatrutide include glucagon in their design.
Important Note
This page is for education only. It is not medical advice. Survodutide and retatrutide are not FDA approved and are not available as prescription medications outside of clinical trials. Information here reflects early-stage trial data, which can change significantly in Phase 3. Do not attempt to source investigational drugs outside of formal clinical trial enrollment.
Related
- Survodutide
- Retatrutide
- Can You Microdose Retatrutide?
- Does Retatrutide Cause Nausea?
- How Long Does Retatrutide Take to Work?
- How to Reconstitute Retatrutide
- Peptides for Fat Loss
Built by medical professionals, gym rats, and experienced biohackers
Tracking an approved GLP-1 protocol while keeping an eye on what is coming next? DoseVault helps you log your current doses and organize your protocol so you can see exactly how you are responding week over week.